PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Genomic instability characterizes high-grade serous ovarian cancer (HGSOC), with one half of all tumors displaying defects i...

Full description

Bibliographic Details
Main Authors: Stergios Boussios, Afroditi Karathanasi, Deirdre Cooke, Cherie Neille, Agne Sadauskaite, Michele Moschetta, Nikolaos Zakynthinakis-Kyriakou, Nicholas Pavlidis
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Diagnostics
Subjects:
ovarian cancer
BRCA
PARP inhibitors
homologous recombination
companion diagnostic
toxic effects
resistance mechanism
Online Access:https://www.mdpi.com/2075-4418/9/2/55

Internet

https://www.mdpi.com/2075-4418/9/2/55

Similar Items